News and Press - JDRF T1D Fund

Veralox Therapeutics Announces FDA Orphan Drug Designation for VLX-1005

January 26, 2021 | FREDERICK, MD

Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia

January 12, 2021 | FREDERICK, Md

Immunocore announces closing of $75.0 Million Series C round

January 11, 2021 | OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US

Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA for INV-101 for the Treatment of Prader-Willi Syndrome

January 07, 2021 | MONTREAL

T1D Fund in the News

JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection

December 09, 2020